{
    "cancer_info": {
        "cancer_name": "Cervical Cancer"
    },
    "diagnosis_recommendations": {
        "examinations": [
            "History and physical exam",
            "Pelvic exam",
            "Pap smear",
            "Smoking cessation counseling",
            "HIV testing",
            "Cervical biopsy",
            "Cone biopsy (cold knife preferred)",
            "LEEP (if margins intact)",
            "Endocervical curettage (ECC)",
            "Histologic review",
            "HPV testing",
            "CBC",
            "Platelets",
            "Renal function tests",
            "Liver function tests",
            "SCC antigen monitoring",
            "Pelvic MRI",
            "FDG-PET/CT",
            "CT chest/abdomen/pelvis",
            "Chest radiography",
            "Cystoscopy (if bladder involvement suspected)",
            "Proctoscopy (if bowel involvement suspected)"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Stage IA1 (no LVSI)",
            "risk_group": "Low risk",
            "treatment_plans": [
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "Fertility-desiring",
                    "plan_name": "Conization",
                    "plan_details": "Cold knife conization with margin assessment",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "Non-fertility-desiring",
                    "plan_name": "Simple hysterectomy",
                    "plan_details": "Type A hysterectomy",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Stage IA1 (with LVSI)",
            "risk_group": "Intermediate risk",
            "treatment_plans": [
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "",
                    "plan_name": "Radical hysterectomy",
                    "plan_details": "Type B + lymphadenectomy",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "",
                    "plan_name": "Chemoradiation",
                    "plan_details": "EBRT + concurrent platinum-based chemotherapy",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Alternative"
                }
            ]
        },
        {
            "staging_criteria": "Stage IA2-IB1",
            "risk_group": "Low risk (meeting fertility-sparing criteria)",
            "treatment_plans": [
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "Fertility-desiring",
                    "plan_name": "Cone biopsy + SLN mapping",
                    "plan_details": "With pelvic lymphadenectomy if SLN mapping fails",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "Fertility-desiring (IB1)",
                    "plan_name": "Radical trachelectomy",
                    "plan_details": "With SLN mapping",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Option"
                },
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "Non-fertility-desiring",
                    "plan_name": "Simple hysterectomy",
                    "plan_details": "Type A + SLN mapping",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Stage IB1-IIA1",
            "risk_group": "Not meeting fertility-sparing criteria",
            "treatment_plans": [
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "",
                    "plan_name": "Radical hysterectomy",
                    "plan_details": "Open abdominal Type C1 + pelvic/para-aortic lymphadenectomy",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Stage IB3-IIA2",
            "risk_group": "Locally advanced",
            "treatment_plans": [
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "",
                    "plan_name": "Chemoradiation",
                    "plan_details": "Cisplatin (40 mg/m² weekly) + EBRT + brachytherapy",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "",
                    "plan_name": "Radical hysterectomy",
                    "plan_details": "With lymphadenectomy",
                    "nccn_evidence_category": "Category 2B",
                    "nccn_recommendation_category": "Alternative"
                }
            ]
        },
        {
            "staging_criteria": "Stage IIB-IVA",
            "risk_group": "Locally advanced",
            "treatment_plans": [
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "FIGO 2014 III-IVA",
                    "plan_name": "Pembrolizumab + chemoradiation",
                    "plan_details": "Concurrent with cisplatin/carboplatin + EBRT + brachytherapy",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "FIGO 2018 III-IVA",
                    "plan_name": "Pembrolizumab + chemoradiation",
                    "plan_details": "Concurrent with platinum-based therapy",
                    "nccn_evidence_category": "Category 2B",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "Para-aortic node involvement",
                    "plan_name": "Extended-field RT",
                    "plan_details": "Pelvic + para-aortic radiation + concurrent chemo",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Stage IVB/Recurrent",
            "risk_group": "Metastatic",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "PD-L1 CPS ≥1",
                    "plan_name": "Pembrolizumab + chemo ± bevacizumab",
                    "plan_details": "Pembrolizumab + cisplatin/carboplatin + paclitaxel ± bevacizumab",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "PD-L1 negative",
                    "plan_name": "Platinum/taxane ± bevacizumab",
                    "plan_details": "Cisplatin/carboplatin + paclitaxel ± bevacizumab",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Second-line treatment",
                    "patient_subgroup": "Biomarker-agnostic",
                    "plan_name": "Tisotumab vedotin",
                    "plan_details": "TF-directed antibody-drug conjugate",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Subsequent treatment",
                    "patient_subgroup": "MSI-H/dMMR",
                    "plan_name": "Pembrolizumab",
                    "plan_details": "Monotherapy",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Subsequent treatment",
                    "patient_subgroup": "HER2+",
                    "plan_name": "Trastuzumab deruxtecan",
                    "plan_details": "HER2-directed therapy",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Small cell neuroendocrine carcinoma (NECC)",
            "risk_group": "Aggressive",
            "treatment_plans": [
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "",
                    "plan_name": "Chemoradiation",
                    "plan_details": "Cisplatin/etoposide + RT ± brachytherapy",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Adjuvant therapy",
                    "patient_subgroup": "",
                    "plan_name": "Systemic chemotherapy",
                    "plan_details": "Cisplatin/etoposide ± atezolizumab",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Post-surgery",
            "risk_group": "Intermediate risk (Sedlis criteria)",
            "treatment_plans": [
                {
                    "treatment_line": "Adjuvant treatment",
                    "patient_subgroup": "LVSI + deep invasion + size >2cm",
                    "plan_name": "Pelvic EBRT",
                    "plan_details": "45-50 Gy ± chemotherapy",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Post-surgery",
            "risk_group": "High risk (positive nodes/margins/parametria)",
            "treatment_plans": [
                {
                    "treatment_line": "Adjuvant treatment",
                    "patient_subgroup": "",
                    "plan_name": "Chemoradiation",
                    "plan_details": "EBRT + concurrent cisplatin",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": [
            "PD-L1 CPS ≥1: Predicts response to pembrolizumab/cemiplimab immunotherapy (OS benefit in KEYNOTE-826)",
            "MSI-H/dMMR: Indicates pembrolizumab efficacy (ORR 57% in KEYNOTE-158)",
            "TMB-H (≥10 mut/Mb): Predicts checkpoint inhibitor response",
            "HER2+ (IHC 3+/2+ FISH+): Eligibility for trastuzumab deruxtecan (ORR 24%)",
            "NTRK fusions: Predicts response to larotrectinib/entrectinib (ORR >75%)",
            "RET fusions: Predicts response to selpercatinib",
            "HPV-associated tumors: Better prognosis than HPV-independent subtypes (e.g., gastric-type adenocarcinoma)",
            "Tissue Factor (TF): Biomarker for tisotumab vedotin efficacy"
        ]
    },
    "guideline_id": "（2025.V1）NCCN临床实践指南：宫颈癌.txt"
}